CD274 and non-small cell lung carcinoma: (95) found PD-1 inhibitors had better OS and PFS than PD-L1 inhibitors in various cancers, it’s uncertain if the three forms of ICIs, PD-1, PD-L1, and CLTA-4 inhibitors in NSCLC patients with BMs have different intracranial activity.